ClinicalTrials.govpublic full text
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
hcc - hepatocellular carcinoma, hepatocellular carcinoma, iparomlimab/tuvonralimab, stereotactic body radiation therapy, lenvatinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 876138
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.